

MHS Home/Alternate Site Infusion Services Ublituximab-xiyy (Briumvi) Infusion Order Set

ALL ORDERS MUST BE SIGNED AND DATED BY PRESCRIBING PROVIDER

Patient Name: _____	DOB: ____/____/____	Weight: _____ lb/kg
----------------------------	----------------------------	----------------------------

Patient Phone Number: (____) ____-____	Requested Date of Service: ____/____/____
---	--

Patient Allergies: _____

Diagnosis: _____ **ICD – 10 Code:** _____

- Z45.2: Encounter for adjustment and management of vascular access device
- Z95.828: Presence of other vascular implants and grafts

Baseline Labs required:

- | | | |
|--------------------------------------|----------------------|---------------|
| • HBV screening | Date: ____/____/____ | Result: _____ |
| • Quantitative serum immunoglobulins | Date: ____/____/____ | Result: _____ |
| • Pregnancy test | Date: ____/____/____ | Result: _____ |

Maintenance Labs recommended:

Pregnancy testing prior to each dose in patients who may become pregnant.

Lab Orders: _____

Additional Requirements: In addition to order, please include H&P with documentation to support diagnosis. Must include ICD-10 Code(s) and supporting labs. **** Emergency phone number for provider _____ (required) ****

Provider Order for Ublituximab-xiyy (Briumvi) Infusion

ORDERS WITH CHECK
BOXES

When an order is optional (those with check boxes), providers are responsible for indicating a check mark in the box next to the order. Orders left unchecked will not be initiated.

Pre-Medication(s):

- Methylprednisolone: 125 mg IV once, 30 minutes prior to each infusion
- Diphenhydramine: 25 mg IV once, 30-60 minutes prior to infusion
- Acetaminophen: 650 mg tab/cap by mouth once, 30-60 minutes prior to infusion (patient may provide own supply)

Biologic Infusion:

Ublituximab-xiyy (Briumvi) in 250 mL NS

- Initiation: 150 mg IV x 1 on Day 1, then 450 mg IV x 1 on day 15
- Maintenance: 450 mg IV every 24 weeks (start 24 weeks after 150 mg dose)

Infuse via infusion pump using rate titration:

- 150 mg: start at 10 mL/hr x 30 min; then 20 mL/hr x 30 min; then 35 mL/hr x 60 min; then 100 mL/hr for remaining infusion (approximate total duration 4 hours).
- 450 mg: start at 100 mL/hr x 30 min, then 400 mL/hr for remaining infusion (approximate total duration 1 hour).

Additional Medications:

- 0.9% NaCl (NS) PF flush in 10 mL syringe: Administer 5 – 30 mL IV as needed for establishing and maintaining IV access and for flushing IV line post infusion.
- Heparin: 100 units/mL for port OR 10 units/mL for other central line/midline, 3-5 mL as needed for de-accessing line.
- Cathflo (alteplase) 2 mg: Instill 2 mg (2 mL) into occluded catheter as needed for CVC/CVAD occlusion.
- Diphenhydramine 25 mg IV once, as needed for itching.
- Acetaminophen 325-650 mg tab/cap by mouth once, as needed for pain.

CONTINUED ON NEXT PAGE

FOR MHS HOME/ALTERNATE SITE INFUSION SERVICES USE ONLY

Patient Identification:

Name:
MRN:
DOB:

Pre-printed order – Page 1 of 2
Ublituximab-xiyy (Briumvi) Order Set
MultiCare

Skilled Nurse Interventions:

- Admit (first visit) patient to services for home infusion therapy of Ublituximab-xiyy (Briumvi).
- Complete Skilled Nurse visit with each infusion for ongoing home infusion therapy of Ublituximab-xiyy (Briumvi).
- Obtain vital signs (TPR & B/P) at baseline, with each infusion rate titration, completion of infusion, and 60 minutes post-infusion (for first 2 infusions only. Post-infusion monitoring for subsequent doses at physician's discretion).
- Obtain patient weight at each visit.
- Establish IV access and flush per policy to maintain patency.
- Draw labs as ordered.
- Administer pre-medications as prescribed.
- Add Ublituximab-xiyy (Briumvi) to sodium chloride 0.9% (NS) for a total volume of 250 mL.
- Infuse Ublituximab-xiyy (Briumvi) as prescribed.
- Once infusion complete, flush IV line with sodium chloride 0.9% (NS) as prescribed.
- If vital signs are stable after infusion and any observation period, Skilled Nurse will discontinue IV access and complete visit.

If Hypersensitivity Reaction Develops (fever, chills, hypotension, rigors, itching, rash, etc.):

The Skilled Nurse will:

- STOP THE INFUSION.
- Administer emergency medications as prescribed (below).
- For mild infusion reaction, may restart the infusion at a slower rate (verified with pharmacist) if symptoms resolve with medication.
- Contact Emergency Medical Services (EMS/911) if indicated.
- Increase vital sign monitoring to every 5 minutes.
- Contact provider via emergency phone number _____ **(required)** for additional instructions.
- Notify MHS Home/Alternate Infusion Site Pharmacist AND Nurse Supervisor

Emergency Medications: To be administered by skilled nurse as needed for hypersensitivity reactions.

- **Diphenhydramine 50 mg/mL solution:** Inject **0.5 mL** (25 mg) into the vein via slow IV push over at least 2 minutes as needed for rash, itching, hives, flushing of skin, and/or mild-to-moderate hypersensitivity reaction. May give IM if no IV access is available. Max dose = 50 mg.
- **Methylprednisolone sodium succinate (SOLU-MEDROL) 125 mg/2 mL solution:** Inject **2 mL** (125 mg) into the vein as a slow IV push over at least 3 minutes once, as needed for hives, flushing of the skin, shortness of breath, chest tightness, tachycardia (HR>140 bpm), and/or moderate-to-severe hypersensitivity reaction. May give IM if no IV access is available.
- **EPINEPHrine (Adrenalin) 1 mg/mL solution:** Inject **0.3 mL** (0.3 mg) intramuscular every 5-15 minutes as needed (maximum 3 doses) for severe allergic reaction or anaphylaxis AND call 911 and provider.
- **Acetaminophen (Tylenol) 325 mg tab:** Take **2 tablets** (650 mg) by mouth as needed for fever (PRN for temperature > 101F/38.3C) and/or mild-to-moderate hypersensitivity reaction.
- **0.9% NaCl (NS) solution:** Infuse **500 mL** into the vein via gravity as needed at a rate needed to maintain IV access.
- **Oxygen:** Initiate oxygen by RN PRN chest pain or dyspnea to keep SpO2>90%. For 1-6 LPM, use NC. For 6-10 LPM, use simple mask.

Code Status: Please note, patients will be considered FULL Code unless marked otherwise. If the patient has a POLST, advance directive or living will, please include a copy with the orders.

Was consent obtained: Yes No (if yes, please send DOCUMENTATION of consent with order)

I certify that this patient is safe and appropriate to receive therapy from Home Infusion Services.

Provider Signature: _____ Printed Name: _____ Date: _____

NPI: _____ Orders expire in 12 months unless otherwise specified: _____

Provider/Clinic Information:

Address: _____

Phone #: _____ Fax#: _____

Return completed orders to:

MultiCare Home/Alternate Site Infusion Services
253-459-6650 (phone) / 253-864-2785 (fax)

FOR MHS HOME/ALTERNATE SITE INFUSION SERVICES USE ONLY

Patient Identification:

Name: _____

MRN: _____

DOB: _____

Pre-printed order – Page 2 of 2
Ublituximab-xiyy (Briumvi) Order Set
MultiCare

Revised 10/24